Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-10-09
2007-10-09
Bragdon, Kathleen Kerr (Department: 1656)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007400, C435S007920, C435S194000, C530S388260, C514S312000, C514S350000
Reexamination Certificate
active
11285841
ABSTRACT:
The present invention provides methods for detecting activation of ATM kinase, DNA damage, and DNA damaging agents. Further provided are antibodies which specifically recognize the phosphorylation state of Ataxia Telangiectasia-Mutated (ATM) kinase. Methods of identifying agents which modulate the activation and activity of ATM kinase are also provided.
REFERENCES:
patent: 2233970 (1941-03-01), Andersag et al.
patent: 4181725 (1980-01-01), Voorhees et al.
patent: 4260615 (1981-04-01), Raether et al.
patent: 4284627 (1981-08-01), Raether et al.
patent: 4421920 (1983-12-01), Baudouin et al.
patent: 4431807 (1984-02-01), Strube et al.
patent: 5134168 (1992-07-01), Bitonti et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5278173 (1994-01-01), Davis
patent: 5314894 (1994-05-01), Stecher et al.
patent: 5340803 (1994-08-01), Rubin
patent: 5430039 (1995-07-01), Roberts-Lewis et al.
patent: 5596002 (1997-01-01), Hofheinz et al.
patent: 5599681 (1997-02-01), Epstein et al.
patent: 5624938 (1997-04-01), Pernis
patent: 5635515 (1997-06-01), Chauffert et al.
patent: 5639761 (1997-06-01), Francois et al.
patent: 5668149 (1997-09-01), Oroszlan et al.
patent: 5948791 (1999-09-01), Hofheinz et al.
patent: 6348311 (2002-02-01), Kastan et al.
patent: 6387640 (2002-05-01), Kastan et al.
patent: 6417177 (2002-07-01), Nelson
patent: 6475518 (2002-11-01), Baumgart et al.
patent: 6579898 (2003-06-01), Humphrey
patent: 2002/0044919 (2002-04-01), Yu
patent: 2002/0169140 (2002-11-01), Prendergast
patent: 2004/0092583 (2004-05-01), Shanahan-Prendergast
patent: WO 98/56391 (1998-02-01), None
patent: WO-01/52868 (2001-07-01), None
patent: WO-02/13826 (2002-02-01), None
patent: WO-03/013535 (2003-02-01), None
Al-Herz, A., et al., “Survey of antimalarial use of lupus pregnancy and lactation”, J. Rheumatol., 2002, Vo. 29, pp. 700-706.
Arnold, A.M., et al., “Interaction of VP16-213 with the DNA repair antagonist chloroquine,” Cancer Chemotherapy and Pharmacology, 1982, vol. 7, pp. 123-126.
Azzam, E.I., “Low dose ionizing radiation decreases the frequency of neoplastic transformation to a level below the spontaneous rate in C3h 10T1/2 cells”, Radiation Res., 1996, vol. 146, pp. 369-373.
Bakkenist, C.J., and Kastan, M.B., “DNA damage activates ATM through intermolecular autophosphorylation and dimer dissocation”, Nature, 2003, vol. 421, pp. 499-506.
Bartkova, J., et al., “DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis”, Nature, 2005, vol. 434, pp. 864-869.
Bartkova, J., et al., “ATM activation in normal human tissues and testicular cancer”, Cell Cycle, vol. 4(6), pp. 838-845.
Bhattarcharjee, D., “Role of radioadaptation on radiation-induced thymic lymphoma in mice”, Mutation Res., 1996, vol. 358, pp. 231-235.
Bielicky T., et al., “Effect of chloroquine-diphosphate administration on the skin damage in guinea pigs caused by x-ray irradiation, ”Journal of Investigative Dermatology, 1966, 47(2), pp. 73-77.
Boniver, J., et al., “Cellular events in radiation-induced lymphomagenesis”, Int. J. Radiat. Biol., 1990, vol. 57, pp. 693-698.
Briceno, Eduardo, et al., “Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine”, Neurosurg. Focus, 2003, vol. 14, No. 2, pp. 1-6.
Cadet, J, et al., “Radiation-induced DNA damage: formation, measurement, and biochemical features”, J Environ Pathol Toxicol Oncol., 2004, vol. 23, pp. 33-43.
Cobreros et al., “Modifiers of radiation action on DNA screened by analytical ultracentrifugation,” Radiation Research, 1982, 92(2), pp. 255-267.
Collis, S. J., et al., “Evasion of early cellular response mechanisms following low level radiation-induced DNA damage”, The Journal of Biological Chemistry, Nov. 26, 2004, vol. 279, No. 48, pp. 49624-49632.
Costedoat-Chalumeau, N., et al., “Safety of hydroxychloroquine in pregnant patients with connective tissue diseases”, Arthritis Rheumatism, 2003, vol. 48, pp. 3207-3211.
Ducharme, J., et al., “Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements,” Clinical Pharmacokinetics, 1996, 31(4), pp. 257-274.
Feinendegen, L.E., et al., “Intracellular stimulation of biochemical control mechanisms”, Healthy Physics, 1987, vol. 52, pp. 663-669.
Fernandez, Y., et al., “Effect of systemic lupus erythematosus (SLE) treatment drugs on G1-101A breast tumor cell growth,” Life Sciences, 2000, vol. 67, pp. 567-575.
Freeman, R.G., et al., “Skin cancer and the sun,” CA Cancer J Clin., 1967, vol. 17, No. 5, pp. 231-239.
Frigerio, N.A., et al., “Carcinogenic and genetic hazard from background radiation. Biological and environmental effects of low-level radiation”, IAEA, 1976, vol. II, pp. 385-393.
Haberkorn, A., et al., “Antimalarial activity in animals of the optical isomers of chloroquine diphosphate”, Trop Med Parasitol, 1979, vol. 30, pp. 308-312.
Hagihara, H., et al., “Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107,” Cancer Research, Jan. 15, 2000, vol. 60, pp. 230-234.
Horejsi, Z., et al., “Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation”, Oncogene, 2004, vol. 23, pp. 3122-3127.
Ikushima, T., et al., “Radioadaptive response; Efficient repair of radiation induced DNA dmaage in adapted cells”, Mutation Res., 1996, vol. 358, pp. 193-198.
Inoue, S. et al., “Antimelanoma activity of chloroquine, an antimalarial agent with high affinity for melanin,” Pigment Cell Research, 1993, vol. 6., pp. 354-358.
Kaplan, H.S., et al., “A quantitative dose-response study of lymphoid-tumor development in irradiated C57 black mice”, J Natl Cancer Inst, 1952, vol. 13, pp. 185-208.
Kastan, M.B., et al., “Multiple signaling pathways involving ATM”, Cold Spring Harb Symp Quant Biol, 2000, vol. 65, pp. 521-526.
Kawanishi et al., “Mechanism of guanine-specific DNA damage by oxidative stress and its role in carcinogenesis and aging,” Mutation Research, 2001, 488(1), pp. 65-76.
Kim, S.H., et al., “Enhancement of the radiation response of cultured tumor cells by chloroquine,” Cancer: A Journal of the American Cancer Society, Sep. 1973, vol. 32, pp. 536-540.
Kitagawa, R., et al., “Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-NBS1-BRCA1 pathway”, Genes Dev., 2004, 18(12), pp. 1423-1438.
Knox, John M., et al., “Prophylactic Use of Chloroquine to Prevent Skin Cancer”, Archives of Dermatology, Mar. 1963, vol. 87, pp. 315-322.
Knox, J.M., et al., “Effect of chloroquine on erythematous and carcinogenic response to ultraviolet light,” A.M.A. Archives of Dermatology, Apr. 1960, vol. 81, pp. 122/570-128/576.
Knox, J.M. et al., “Light sensitive eruptions treated with atabrine and chloroquine”, The Journal of Investigative Dermatology, 1954, vol. 22, pp. 11-16.
Kumatori, T., et al., “Follow up studies over a 25 year period on the Japanese fishermen exposed to radioactive fallout in 1954”, pp. 35-54, in Hubner K.F., and Fry, A.A., eds., The medical basis for radiation preparedness, Elsevier, New York, 1980.
Lagneaux, L., et al., “Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors”, British Journal of Haematology, 2001, vol. 112, pp. 344-352.
Lee, J.-H., and Paull, T. T., “Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex”, Science, 2004, vol. 304, pp. 93-96.
Lieberman, L.M. et al., “Treatment doses ofT31l-labeled chloroquine analog in normal and malignant melanoma dog,” Journal of Nuclear Medicine, Jan. 1971, vol. 12, No. 4, pp. 153-159.
Mifune, M., et al., ȁ
Bakkenist Christopher
Kastan Michael B.
Bragdon Kathleen Kerr
Darby & Darby
Gebreyesus Kagnew
St. Jude Children's Research Hospital
LandOfFree
ATM kinase compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ATM kinase compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ATM kinase compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3872945